Form4insider filings, from the source

SEC Form 4 · accession 0001246360-15-001755

SYNAGEVA BIOPHARMA CORP · GEVA

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner
Anthony Quinn
Officer — EVP, CMO & Head of R&D
Period of report
Apr 6, 2015
Accepted (ET)
Apr 8, 2015 · 6:35 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000911326

Table I — non-derivative securities

SecurityDateCodeSharesPriceA/DOwned afterD/INature of ownership
Common StockF1,F2,F3Apr 6, 2015A42$76.88A25,637D
Common StockApr 6, 2015M10,000$0.95A35,637D
Common StockApr 6, 2015M9,503$23.00A45,140D
Common StockApr 6, 2015S29,503$93.76D15,637D

Table II — derivative securities

SecurityConv. / exercise priceDateCodeSharesA/DExercisableExpiresUnderlyingUnderlying sharesOwned afterD/I
Stock Option (Right to Buy)F5$0.95Apr 6, 2015M10,000D—Oct 7, 2019Common Stock10,0008,964D
Stock Option (Right to Buy)F6$23.00Apr 6, 2015M9,503D—Dec 20, 2021Common Stock9,50320,497D

Explanation of responses